CA1292946C - Methode pour empecher la formation d'adherences apres une intervention chirurgicale par l'administration topique d'un medicament anti-inflammatoire non steroidien - Google Patents

Methode pour empecher la formation d'adherences apres une intervention chirurgicale par l'administration topique d'un medicament anti-inflammatoire non steroidien

Info

Publication number: CA1292946C
Authority: CA; Canada
Prior art keywords: ibuprofen; drug; tolmetin; composition; vesicle
Prior art date: 1986-11-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000523793A

Other languages

English (en)

Inventor

Warren Douglas Sheffield

Douglas Brian Johns

Shalaby Wahba Shalaby

Gere Stodder Dizerega

Leroy L. Richer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ethicon Inc

Original Assignee

Ethicon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-11-25

Filing date

1986-11-25

Publication date

1991-12-10

1986-11-25 Application filed by Ethicon Inc filed Critical Ethicon Inc

1986-11-25 Priority to CA000523793A priority Critical patent/CA1292946C/fr

1991-12-10 Application granted granted Critical

1991-12-10 Publication of CA1292946C publication Critical patent/CA1292946C/fr

2008-12-10 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title claims abstract description 44
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title claims abstract description 43
230000015572 biosynthetic process Effects 0.000 title claims abstract description 18
208000031737 Tissue Adhesions Diseases 0.000 title claims description 9
230000002401 inhibitory effect Effects 0.000 title claims description 7
238000011200 topical administration Methods 0.000 title abstract description 5
238000000034 method Methods 0.000 title description 34
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 56
229960001680 ibuprofen Drugs 0.000 claims abstract description 55
239000003814 drug Substances 0.000 claims abstract description 51
229940079593 drug Drugs 0.000 claims abstract description 36
229960001017 tolmetin Drugs 0.000 claims abstract description 29
UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims abstract description 29
208000014674 injury Diseases 0.000 claims abstract description 19
MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 claims abstract description 18
229960004492 suprofen Drugs 0.000 claims abstract description 18
230000008733 trauma Effects 0.000 claims abstract description 18
150000003904 phospholipids Chemical class 0.000 claims abstract description 12
229920000642 polymer Polymers 0.000 claims abstract description 11
238000013270 controlled release Methods 0.000 claims abstract description 4
239000003094 microcapsule Substances 0.000 claims description 31
239000000203 mixture Substances 0.000 claims description 28
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 12
239000004480 active ingredient Substances 0.000 claims description 10
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 9
235000010445 lecithin Nutrition 0.000 claims description 9
229940067606 lecithin Drugs 0.000 claims description 9
239000000787 lecithin Substances 0.000 claims description 9
150000002148 esters Chemical class 0.000 claims description 7
150000004665 fatty acids Chemical group 0.000 claims description 7
150000003839 salts Chemical class 0.000 claims description 7
235000012000 cholesterol Nutrition 0.000 claims description 6
235000014113 dietary fatty acids Nutrition 0.000 claims description 6
239000000194 fatty acid Substances 0.000 claims description 6
229930195729 fatty acid Natural products 0.000 claims description 6
239000004094 surface-active agent Substances 0.000 claims description 5
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 3
229920001577 copolymer Polymers 0.000 claims description 3
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 2
VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims description 2
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
229920001519 homopolymer Polymers 0.000 claims 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
239000007864 aqueous solution Substances 0.000 claims 1
125000004122 cyclic group Chemical group 0.000 claims 1
239000004310 lactic acid Substances 0.000 claims 1
235000014655 lactic acid Nutrition 0.000 claims 1
235000011069 sorbitan monooleate Nutrition 0.000 claims 1
239000001593 sorbitan monooleate Substances 0.000 claims 1
229940035049 sorbitan monooleate Drugs 0.000 claims 1
239000003981 vehicle Substances 0.000 abstract description 25
239000004005 microsphere Substances 0.000 abstract 1
241000283973 Oryctolagus cuniculus Species 0.000 description 53
239000000243 solution Substances 0.000 description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
238000002474 experimental method Methods 0.000 description 20
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
239000002502 liposome Substances 0.000 description 18
238000011156 evaluation Methods 0.000 description 16
239000002953 phosphate buffered saline Substances 0.000 description 16
238000001356 surgical procedure Methods 0.000 description 16
150000002632 lipids Chemical class 0.000 description 12
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
230000000694 effects Effects 0.000 description 9
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 9
229920000053 polysorbate 80 Polymers 0.000 description 9
-1 see Singer Chemical compound 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
238000005299 abrasion Methods 0.000 description 8
230000000740 bleeding effect Effects 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
239000000725 suspension Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 8
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
230000004044 response Effects 0.000 description 6
230000029663 wound healing Effects 0.000 description 6
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
238000005481 NMR spectroscopy Methods 0.000 description 5
239000002253 acid Substances 0.000 description 5
239000012530 fluid Substances 0.000 description 5
238000004108 freeze drying Methods 0.000 description 5
238000013508 migration Methods 0.000 description 5
230000005012 migration Effects 0.000 description 5
239000003960 organic solvent Substances 0.000 description 5
229920002451 polyvinyl alcohol Polymers 0.000 description 5
159000000000 sodium salts Chemical class 0.000 description 5
239000002904 solvent Substances 0.000 description 5
NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000003246 corticosteroid Substances 0.000 description 4
229960001334 corticosteroids Drugs 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
210000003200 peritoneal cavity Anatomy 0.000 description 4
238000011555 rabbit model Methods 0.000 description 4
238000007910 systemic administration Methods 0.000 description 4
238000005406 washing Methods 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
239000002260 anti-inflammatory agent Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000036512 infertility Effects 0.000 description 3
208000000509 infertility Diseases 0.000 description 3
229960003299 ketamine Drugs 0.000 description 3
238000002350 laparotomy Methods 0.000 description 3
239000002674 ointment Substances 0.000 description 3
229960000649 oxyphenbutazone Drugs 0.000 description 3
HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 3
230000002265 prevention Effects 0.000 description 3
238000003860 storage Methods 0.000 description 3
210000004291 uterus Anatomy 0.000 description 3
LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
238000001949 anaesthesia Methods 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940121363 anti-inflammatory agent Drugs 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000002844 continuous effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000036541 health Effects 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
239000000693 micelle Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
210000004303 peritoneum Anatomy 0.000 description 2
230000002980 postoperative effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000005086 pumping Methods 0.000 description 2
230000001850 reproductive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
ADTGIGSPQHDPLT-UHFFFAOYSA-M sodium;2-[4-(thiophene-2-carbonyl)phenyl]propanoate Chemical compound [Na+].C1=CC(C(C([O-])=O)C)=CC=C1C(=O)C1=CC=CS1 ADTGIGSPQHDPLT-UHFFFAOYSA-M 0.000 description 2
238000000527 sonication Methods 0.000 description 2
238000007738 vacuum evaporation Methods 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
206010000050 Abdominal adhesions Diseases 0.000 description 1
208000034656 Contusions Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
208000035874 Excoriation Diseases 0.000 description 1
244000228957 Ferula foetida Species 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000034693 Laceration Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010034650 Peritoneal adhesions Diseases 0.000 description 1
241000009328 Perro Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
206010060932 Postoperative adhesion Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
241000534944 Thia Species 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
230000003872 anastomosis Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000008602 contraction Effects 0.000 description 1
230000009519 contusion Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
230000035558 fertility Effects 0.000 description 1
JFUIHGAGFMFNRD-UHFFFAOYSA-N fica Chemical compound FC1=CC=C2NC(C(=O)NCCS)=CC2=C1 JFUIHGAGFMFNRD-UHFFFAOYSA-N 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000013505 freshwater Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
230000036407 pain Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001936 parietal effect Effects 0.000 description 1
210000000505 parietal peritoneum Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229940051841 polyoxyethylene ether Drugs 0.000 description 1
229920000056 polyoxyethylene ether Polymers 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
238000010926 purge Methods 0.000 description 1
239000008213 purified water Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
108010080511 serum sodium transport inhibitor Proteins 0.000 description 1
WZWGGYFEOBVNLA-UHFFFAOYSA-N sodium;dihydrate Chemical compound O.O.[Na] WZWGGYFEOBVNLA-UHFFFAOYSA-N 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
239000008348 synthetic phosphatidyl choline Substances 0.000 description 1
QGUALMNFRILWRA-UHFFFAOYSA-M tolmetin sodium Chemical compound [Na+].C1=CC(C)=CC=C1C(=O)C1=CC=C(CC([O-])=O)N1C QGUALMNFRILWRA-UHFFFAOYSA-M 0.000 description 1
229960002044 tolmetin sodium Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1

Landscapes

Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA000523793A 1986-11-25 1986-11-25 Methode pour empecher la formation d'adherences apres une intervention chirurgicale par l'administration topique d'un medicament anti-inflammatoire non steroidien Expired - Lifetime CA1292946C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000523793A CA1292946C (fr)	1986-11-25	1986-11-25	Methode pour empecher la formation d'adherences apres une intervention chirurgicale par l'administration topique d'un medicament anti-inflammatoire non steroidien

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000523793A CA1292946C (fr)	1986-11-25	1986-11-25	Methode pour empecher la formation d'adherences apres une intervention chirurgicale par l'administration topique d'un medicament anti-inflammatoire non steroidien

Publications (1)

Publication Number	Publication Date
CA1292946C true CA1292946C (fr)	1991-12-10

Family

ID=4134429

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000523793A Expired - Lifetime CA1292946C (fr)	1986-11-25	1986-11-25	Methode pour empecher la formation d'adherences apres une intervention chirurgicale par l'administration topique d'un medicament anti-inflammatoire non steroidien

Country Status (1)

Country	Link
CA (1)	CA1292946C (fr)

1986
- 1986-11-25 CA CA000523793A patent/CA1292946C/fr not_active Expired - Lifetime

Legal Events

Date	Code	Title	Description
2008-12-10	MKEX	Expiry

Publication	Publication Date	Title
US4937254A (en)	1990-06-26	Method for inhibiting post-surgical adhesion formation by the topical administration of non-steroidal anti-inflammatory drug
US4889722A (en)	1989-12-26	Method for inhibiting post-surgical adhesion formation by the topical administration of tissue plasminogen activator
US4877619A (en)	1989-10-31	Liposomal vesicles for intraperitoneal administration of therapeutic agents
EP0225162B1 (fr)	1992-01-22	Inhibition de la formation de l'adhérence postchirurgicale par l'administration topique d'un médicament anti-inflammatoire non stéroide
US4844904A (en)	1989-07-04	Liposome composition
JP4598908B2 (ja)	2010-12-15	カチオン性リポソームとポリデオキシリボヌクレオチドとの複合体
KR970007187B1 (ko)	1997-05-07	개선된 암포테리신 b 리포좀 제조법
KR100315213B1 (ko)	2002-07-03	리포좀생산방법
PT86090B (pt)	1990-11-20	Lipossoma de aerossol em particulas pequenas e preparacoes lipossoma-medicamento para utilizacao em medicina
RU97112399A (ru)	1999-06-10	Пролипосомные порошки для ингаляции
EP0726763B1 (fr)	2000-03-29	Procedes de traitement faisant appel a des formulations de metabolite d'acide arachidonique liposomique unilamellaire
CA1297791C (fr)	1992-03-24	Methode permettant d'inhiber la formation d'adherences a la suite d'une intervention chirurgicale par application topique d'activateur tissulaire du plasminogene
CA1323306C (fr)	1993-10-19	Preparation comprenant une solution lipidique et un agent pharmacologique
CA2508166A1 (fr)	2004-06-24	Compositions et methodes associees aux formulations de lipide:emodine
JP2944756B2 (ja)	1999-09-06	凍結乾燥された、作用物質含有エマルジョン
JPH06507882A (ja)	1994-09-08	滑膜癒着の防止
CA1292946C (fr)	1991-12-10	Methode pour empecher la formation d'adherences apres une intervention chirurgicale par l'administration topique d'un medicament anti-inflammatoire non steroidien
PT87886B (pt)	1993-09-30	Metodo para a prevencao de deposicao de fibrina ou de formacao de adesoes e processo para a preparacao de composicoes terapeuticas para esse fim
Bourlaist et al.	1996	Release kinetics of liposome-encapsulated ganciclovir after intravitreal injection in rabbits
CN102309449B (zh)	2015-01-28	栀子苷或栀子总环烯醚萜苷的脂质体制剂
EP0234897A2 (fr)	1987-09-02	Inhibition de la formation de l'adhérence post-chirurgicale par l'administration topique continue de glucocorticoides
WO1991006310A1 (fr)	1991-05-16	Compositions liposomiques
CN101606907B (zh)	2011-05-11	福莫司汀固体脂质纳米粒及其制备方法
JPH0211515A (ja)	1990-01-16	フエルビナクを含有する製薬学的調製物
WO2024056062A1 (fr)	2024-03-21	Composition d'hormone stéroïde-phospholipide et son procédé de préparation